Inhibitors of kinesin motor proteins - Research and clinical progress

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 4, 2005, Pages 431-436

  Duhl, David M ^a   Renhowe, Paul A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Anticancer; Antifungal; Antimitotic; ATPase; Eg5; Kinesin; KIP 1; KSP; Mitotic spindle; Motor protein

Indexed keywords

BETA CARBOLINE DERIVATIVE; CAPECITABINE; CARBOPLATIN; CK 0106023; DOCETAXEL; GLYCOPROTEIN P; HR 22C16; ISPINESIB; KINESIN; MOLECULAR MOTOR; MONASTROL; PACLITAXEL; PROTEIN INHIBITOR; PYRAZOLINE DERIVATIVE; SB 743921; UNCLASSIFIED DRUG;

CANCER; CANCER THERAPY; CLINICAL TRIAL; HUMAN; MICROTUBULE; MITOSIS; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; REVIEW;

ANIMALS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; KINESIN; TUMOR SUPPRESSOR PROTEINS;

EID: 21444449874     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Endow SA: Kinesin motors as molecular machines. Bioessays (2003) 25(12):1212-1219. Review of the kinesin family of proteins.
2. Seog DH, Lee DH, Lee SK: Molecular motor proteins of the kinesin superfamily proteins (KIFs): Structure, cargo and disease. J Korean Med Sci (2004) 19(1):1-7. Discusses potential therapeutic targets in the kinesin protein family.
3. Coleman PJ, Fraley ME: Inhibitors of the mitotic kinesin spindle protein. Expert Opin Ther Patents (2004) 14(12):1659-1667. Provides a comprehensive review of the patent literature of mitotic kinesin spindle protein inhibitors.
4. Turner J, Anderson R, Quo J, Beraud C, Fletterick R, Sakowicz R: Crystal structure of the mitotic spindle kinesin Eg5 reveals a novel conformation of the neck-linker. J Biol Chem (2001) 276(27):25496-25502. Discusses the structure and function of Eg5.
5. Sakowicz R, Finer JT, Beraud C, Crompton A, Lewis E, Fritsch A, Lee Y, Mak J, Moody R, Turincio R, Chabala JC et al: Antitumor activity of a kinesin inhibitor. Cancer Res (2004) 64(9):3276-3280.
6. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ: Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science(1999) 286(5441):971-974.
7. Yan Y, Sardana V, Xu B, Homnick C, Halczenko W, Buser CA, Schaber M, Hartman GD, Huber HE, Kuo LC: Inhibition of a mitotic motor protein: Where, how, and conformational consequences. J Mol Biol (2004) 335(2):547-554.
8. Chu QS, Holen KD, Rowinsky EK, Wilding G, Volkman JL, Orr JB, Williams DD, Hodge JP, Sabry J: A phase I trial of novel kinesin spindle protein (KSP) inhibitor, SB-715992 administered intravenously once every 21 days. 40th ASCO Annual Meeting, New Orleans, LA, USA (2004) 22(14S):Abs 2078.
9. Williams D, Kathman S, Chu Q, Holen K, Rowinsky E, Wilding G, Mudd P Jr, Herendeen J, Orr J, Pandite L: A phase I study of SB-715992, a novel kinesin protein spindle (KSP) inhibitor: Pharmacokinetic (PK)/pharmacodynamic (PD) modeling of absolute neutrophil counts (ANC). 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland (2004) 2(8):Abs 55.
10. Kappe CO, Shishkin OV, Uray G, Verdino P: X-ray structure, conformational analysis, enantloseparation and determination of absolute configuration of the mitotic kinesin Eg5 inhibitor monastrol. Tetrahedron (2000) 56(13):1859-1862.
11. Cochran JC, Gatial JE 3rd, Kapoor TM, Gilbert SP: Monastrol inhibition of the mitotic kinesin Eg5. J Biol Chem (2005) 280(13):12658-12667.
12. Sakowicz R, Finer JT, Beraud C, Crompton A, Lewis E, Fritsch A, Lee Y, Mak J, Moody R, Turincio R, Chabala JC et al: Antitumor activity of a kinesin inhibitor. Cancer Res (2004) 64(9):3276-3280.
13. Bergnes G, Ha E, Feng B, Yao B, Smith WW, Tochimoto T, Lewis ER, Lee YY, Moody R, Turincio RA, Finer JT et al: Mitotic kinesin-targeted antitumor agents: Discovery, lead optimization and anti-tumor activity of a series of novel quinazolinones as inhibitors of kinesin spindle protein (KSP). Proc Am Assoc Cancer Res (2002) 43:Abs 3648.
14. Gonzales P, Bienek A, Boehme M, Rivali C, Roth S, Wynne H, Piazza G, Weitman S, Wood K, Crompton A, Moody R et al: Breadth of antitumor activity of CK0238273 (SB-715992), a novel inhibitor of the mitotic kinesin KSP. Proc Am Assoc Cancer Res (2002) 43:Abs 1337.
15. Jackson JR, Gilmartin AG, Williams T, McCabe FL, Caulder E, Inlow L, Whitacre M, Mattern M, Bergnes G, Feng B, Smith WW et al: A pharmacodynamic marker of mitosis demonstrates the anti-mitotic activity of SB-715992, an inhibitor of the mitotic kinesin KSP. Proc Am Assoc Cancer Res (2002) 43:Abs 1336.
16. Johnson RK, McCabe FL, Cauder E, Innlow L, Whitacre M, Winkler JD, Bergnes G, Feng B, Smith WW, Morgans D, Wood K et al: SB-715992, a potent and selective inhibitor of KSP mitotic kinesin, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts. Proc Am Assoc Cancer Res (2002) 43:Abs 1335.
17. Burris H 3rd, LoRusso P, Jones S, McCormick J, Willcutt N, Hodge J, Bush P, Pandite L, Sabry J, Ho P: A phase I study to determine the safety and pharmacokinetics of intravenous administration of SB715992 on a once weekly for three consecutive weeks schedule in patients with refractory solid tumors. Eur J Cancer Suppl (2003) 1(5):Abs 570.
18. Cox CD, Breslin MJ, Mariano BJ, Colemen PJ, Buser CA, Walsh ES, Hamilton K, Huber HE, Kohl NE, Torrent M, Yan Y et al: Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett (2005) 15(8):2041-2045.
19. Marcus AI, Peters U, Thomas SL, Garrett S, Zelnak A, Kapoor TM, Giannakakou P: Mitotic kinesin inhibitors induce mitotic arrest and cell death in taxol-resistant and -sensitive cancer cells. J Biol Chem (2005) 280(12):11569-11577.
20. CYTOKINETICS INC (Bergnes G, Ha E, Yiannikourous G, Kalaritis P, Yonce BE, Welday KA): Synthesis of quinazolinones. WO-03070701 (2003).
21. CYTOKINETICS INC (Finer JT, Bergnes G, Feng B, Smith WW, Chabala JC, Morgans DJ): Methods and compositions utilizing quinazolinones. WO-00198278 (2001).
22. CYTOKINETICS INC (Finer JT, Bergnes G, Feng B, Smith WW, Chabala JC): Methods and compositions utilizing quinazolinones. WO-00130768 (2001).
23. CYTOKINETICS INC (Finer JT, Bergnes G, Feng B, Smith WW, Chabala JC, Morgans DJ): Methods and compositions utilizing quinazolinones. WO-00198278 (2001).
24. BRISTOL-MYERS SQUIBB CO (Lombarde LJ, Bhide RS, Kim KS, Lu S): Pyrrolotriazinone compounds and their use to treat diseases. WO-03099286 (2003).
25. ASTRAZENECA AB (Aquila B, Block MH, Davies A, Ezhuthachan J, Filla S, Luke RW, Pontz T, Theoclitou M-E, Zheng X): Novel fused heterocycles and uses thereof. WO-2004078758 (2004).
26. CHIRON CORP (Wang W, Lagniton LM, Constantine RN, Burger MT): Heteroryl-fused pyrimidinyl compounds as anticancer agents. WO-2004111058 (2004).
27. CHIRON CORP (Wang W, Constantine RN, Lagniton LM, Pecchi S, Burger MT, Desai MC): Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents. WO-2004113335 (2004).
28. MERCK & CO INC (Fraley ME, Hoffman WF): Mitotic kinesin inhibitors. WO-03039460 (2003).
29. SMITHKLINEBEECHAM CORP/CYTOKINETICS INC (Bergnes G, Dhanak D, Knight SD, Lu PP, Morgans DJ, Newlander KA): Compounds, compositions and methods. WO-2004055008 (2004).
30. CYTOKINETICS INC/SMITHKLINEBEECHAM CORP (Morgans DJC, Knight SD, Newlander KA, Dhanak D, Zhou H-J, Adams ND): Compounds, compositions and methods. WO-03094839 (2003).
31. CYTOKINETICS INC (Zhou H-J, Bergnes G): Compounds, compositions and methods. WO-2004100873 (2004).
32. MERCK & CO INC (Breslin MJ, Coleman PJ, Cox CD, Culberson JC, Hartman GD, Mariano BJ, Torrent M): Mitotic kinesin inhibitors. WO-03079973 (2003).
33. MERCK & CO INC (Breslin MJ, Coleman PJ, Cox CD, Hartman GD, Mariano BJ): Mitotic kinesin inhibitors. WO-2004037171 (2004).
34. MERCK & CO INC (Fraley ME, Garbaccio RM, Hartman GD, Hoffman WF): Prodrugs of mitotic kinesin inhibitors. WO-2004111193 (2004).
35. MERCK & CO INC (Fraley ME, Garbaccio RM, Olson CM, Tasber ES): Preparation of tetrahydropyridine derivatives as mitotic kinesin inhibitors. WO-2004058700 (2004).
36. MERCK & CO INC (Coleman PJ, Neilson LA): Mitotic kinesin inhibitors. WO-2004112699 (2004).
37. CYTOKINETICS INC (Tomasi A, Morgan BP, Morgans DJ, Mcdonald A, Roof D, Maxon M): Compounds, compositions and methods. WO-2004098494 (2004).
38. CYTOKINETICS INC (Morgans DJ, Morgan BP, Tomasi A, Wang J): Compounds, compositions and methods. WO-2005005382 (2005).